Immune escape by Epstein-Barr virus associated malignancies
Department of Quantitative Health Sciences; Department of Pediatrics
Antigens, Viral; CD4-Positive T-Lymphocytes; CD8-Positive T-Lymphocytes; Cancer Vaccines; Epstein-Barr Virus Infections; HIV Infections; Herpesvirus 4, Human; Humans; Malaria, Falciparum; Neoplasms; Tumor Escape; Virus Activation; Virus Latency
Biostatistics | Epidemiology | Health Services Research | Immunology and Infectious Disease | Pediatrics
Persistent Epstein-Barr virus (EBV) infection remains asymptomatic in the majority of virus carriers, despite the potent growth transforming potential of this virus. The increased frequency of EBV associated B cell lymphomas in immune compromised individuals suggests that tumor-free chronic infection with this virus is in part due to immune control. Here we discuss the evidence that loss of selective components of EBV specific immunity might contribute to EBV associated malignancies, like nasopharyngeal carcinoma, Burkitt's and Hodgkin's lymphoma, in otherwise immune competent patients. Furthermore, we discuss how current vaccine approaches against EBV might be able to target these selective deficiencies.
Rights and Permissions
Citation: Semin Cancer Biol. 2008 Dec;18(6):381-7. Epub 2008 Oct 19. Link to article on publisher's site
Seminars in cancer biology
Munz, Christian and Moormann, Ann M., "Immune escape by Epstein-Barr virus associated malignancies" (2008). Quantitative Health Sciences Publications and Presentations. 413.